Jasper Therapeutics, INC

Jasper Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders, confirming the election of directors and ratification of its independent auditor.

Jasper Therapeutics confirms the terms of contingent value rights (CVRs) issued in connection with its acquisition of Kira Pharmaceuticals, detailing potential milestone payments tied to FDA approval.

Jasper Therapeutics has completed its acquisition of Kira Pharmaceuticals and secured $132 million in private placement financing to advance a combined pipeline of immunology-focused therapies.

Jasper Therapeutics received a notice from Nasdaq indicating its common stock has closed below the $1.00 minimum bid price requirement, with a 180-day period to regain compliance.

Jasper Therapeutics is initiating a comprehensive review of strategic alternatives to maximize shareholder value, including potential asset sales, mergers, or an orderly wind-down.

Jasper Therapeutics announces the resignation of director Christian Nolet and the appointment of Dr. Svetlana Lucas to the Audit Committee.

Jasper Therapeutics reports a significant decrease in R&D expenses for Q1 2026, alongside a substantial increase in cash burn, while facing ongoing litigation and substantial doubt about its ability to continue as a going concern.

Jasper Therapeutics reports increased net losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, while investigating efficacy issues in a key clinical trial.

Jasper Therapeutics reports increased net losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite positive clinical data for briquilimab in urticaria.

Jasper Therapeutics reports a net loss of $21.241 million for Q1 2025, focusing on advancing clinical programs targeting mast cell-driven diseases.

Jasper Therapeutics reports a net loss of $18.6 million for the third quarter of 2024, while highlighting progress in clinical trials for its lead product candidate, briquilimab.

Jasper Therapeutics reported a net loss of $28.3 million for the first half of 2024, while advancing its clinical programs for briquilimab.

Jasper Therapeutics reports positive clinical data for briquilimab in mast cell diseases, but faces significant net losses and substantial doubt about its ability to continue as a going concern.

Jasper Therapeutics' annual report highlights positive preliminary results from clinical trials for briquilimab in chronic urticaria and asthma, signaling a strategic focus on mast cell-driven diseases.

Jasper Therapeutics details its authorized stock, voting rights, anti-takeover provisions, and warrant information in its recent 10-K filing.

Thomas G Wiggans, a Director of Jasper Therapeutics, Inc., received 7,500 shares of common stock on July 31, 2026.

Judith Anne Shizuru, a Director of Jasper Therapeutics, Inc., received 7,500 shares of common stock on July 31, 2026.

Matthew E Ros, Chief Operating Officer of Jasper Therapeutics, Inc., purchased 881 shares of common stock on July 20, 2026.

Patrick J Crutcher, a Director of Jasper Therapeutics, Inc., purchased 888 shares of common stock on July 16, 2026.

Jasper Therapeutics' CEO and President, Jeetinder Singh Mahal, was granted 500,000 stock options with an exercise price of $1.35, vesting over several years.

Jasper Therapeutics' President, CEO, and Director Ron Martell was granted 234,000 stock options with an exercise price of $1.84, vesting over four years.

Jasper Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for July 31, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

Jasper Therapeutics will hold its annual stockholders meeting virtually on July 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

Jasper Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on July 3, 2025, to vote on director elections, auditor ratification, executive compensation, and other matters.

Jasper Therapeutics released a supplement to its proxy statement to correct an error regarding the treatment of abstentions on Proposals 3 and 4 for the upcoming Annual Meeting of Stockholders.

Jasper Therapeutics will hold its annual stockholders meeting virtually on June 6, 2024, to vote on the election of directors, ratification of the accounting firm, and approval of equity incentive and employee stock purchase plans.

Jasper Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, ratification of the accounting firm, and approval of equity incentive and employee stock purchase plans.

Velan Capital Investment Management LP and affiliated entities have increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.88% following the company's acquisition of Kira Pharmaceuticals.

Velan Capital and affiliated entities increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.6% through a recent public offering, acquiring additional shares and warrants.

Millennium Management and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of Jasper Therapeutics, Inc. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G indicating their beneficial ownership of Jasper Therapeutics, Inc. common stock.

Soleus Capital and affiliated entities have filed a Schedule 13G reporting a combined 1% beneficial ownership stake in Jasper Therapeutics, Inc.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 0.5% beneficial ownership stake in Jasper Therapeutics, Inc.

Millennium Management and affiliated entities have reported a 5.8% beneficial ownership stake in Jasper Therapeutics, Inc. common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 6.3% beneficial ownership stake in Jasper Therapeutics Inc. common stock.